Cite
HARVARD Citation
Shen, L. et al. (n.d.). 775TiPA phase III, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). Annals of oncology. p. . [Online].